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PATIENTS suffering from psoriasis frequently have a low serum folate (Knowles,
Shuster and Wells, 1969; Shuster, Marks and Chanarin, 1967). It is usually
accepted that this is due to loss of folate in the psoriatic desquamation (Hild, 1969),
though it has been suggested that increased utilisation of folate is possibly a more
important factor (Touraine, Revuz, Zittoun, Jarret and Tulliez, 1973). No matter
what the true explanation may be, the serum folate is undoubtedly often reduced
in psoriasis, and it was decided to examine the effect of administering folic acid
to patients suffering from psoriasis in the hope that it might be of therapeutic
benefit.
METHOD
A double blind trial using the 5 mg tablet of folic acid (BP) and inert fac-
similes (manufactured by Arthur H. Cox & Co. Ltd., Brighton) was carried out as
follows. Patients sufiering from typical and extensive psoriasis were included in the
trial provided they were over 18 years of age and gave their informed consent.
Before starting the trial, each patient's peripheral blood was examined and the
serum vitamin B12 and folate levels determined. Patients selected for the trial
were allocated at random into test and control groups. Patients in the test group
took one 5 mg tablet of folic acid (BP) twice daily for six weeks, and patients in
the control group took an inert facsimile twice daily for six weeks. The tablets
were dispensed in coded boxes and distributed to the patients at the clinic without
the dermatologists or the patients being aware which boxes contained active and
which inert tablets. Hydroxocobalamin in a dose of 2,000 micrograms was
administered by intramuscular injection to all patients on commencing the trial
and another 1,000 micrograms once weekly until they ended the trial. The
hydroxocobalamin was given as a precaution against the possibility of folic acid
precipitating a neuropathy should any of the patients have incipient Addisonian
anaemia. During the trial no conventional medication for psoriasis such as
dithranol paste was employed, though in some cases emollients were permitted.
Each patient remained under the care of one dermatologist (T.A.J.D., 16; K.W.S.,
5). At the end of the trial period patients were clinically assessed and classified as
showing no definite change, definite improvement or definite deterioration in their
psoriasis.
RESULTS
Twenty-two patients entered the trial and 21 completed it. Table 1 shows that
the two groups did not differ significantly (at P<0.05) with respect to the effects
of the treatment.
100TABLE 1: EFFECT OF FOLIC ACID ADMINISTRATION IN PSORIASIS
Patients
Clinical assessment Folic acid group Control group Total
Definite improvement 3(25.0%) 2(22.2%) 5(23.8%)
No definite change 9(75.0%) 6(66.7%) 15(71.4%)
Definite deterioration 0(-) 1(11.1%) 1 (4.8%)
Total 12(100%) 9(100%) 21(100%)
P=0.78
DISCUSSION
As there is no significant difference in respect of the effect of treatment (at
P<0.05) between the patients who received folic acid and those who received
inert facsimile, there is little evidence for rejection of the null hypothesis that
folic acid and inert tablets have a similar effect on psoriasis. However, with the
relatively small number of patients participating in the trial, only large differences
in treatment effects are likely to be detected at the 5 per cent level.
Apart from the absence of therapeutic benefit, the fact that no evidence of an
adverse effect was detected is of some interest in view of the widespread use of
folic acid antagonists in the treatment or psoriasis.
SUMMARY
A double blind trial of folic acid therapy in psoriasis was carried out in 21
patients over a period of six weeks. The results indicate neither a beneficial nor
an adverse efiect.
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